Active Substance & Generic Molecule Directory
Granisetron Hydrochloride in Malaysia: Registered Brands, Dosages & Price Comparison
Directory of all approved pharmaceutical brands containing Granisetron Hydrochloride registered with the National Pharmaceutical Regulatory Agency (NPRA) / Ministry of Health Malaysia (KKM).
9
Registered Brands
Availability in Malaysia:9 Prescription (MAL-A)
Showing 9 of 9 registered brands
| MAL Reg No | Brand Formulation Name | Strength / Dosage | Classification | Registration Holder | Action |
|---|---|---|---|---|---|
| MAL20116016AZ | Destron Tablet 1mg | 1.12 mg | Prescription (MAL-A) | PHARMANIAGA MANUFACTURING BERHAD | Compare → |
| MAL17107089AZ | GRANIL 3mg/3mL Solution for Injection/Infusion | 3.36mg 3ml | Prescription (MAL-A) | Y.S.P. INDUSTRIES (M) SDN. BHD. | Compare → |
| MAL16045060ACRZ | Granisetron-AFT Solution for Injection 1mg/ml | 1mg/ml 0 | Prescription (MAL-A) | AFT PHARMACEUTICALS (SE ASIA) SDN BHD | Compare → |
| MAL22016020ACZ | Granodex 1mg/ml Solution for Injection or Infusion | 1.12 mg/mL | Prescription (MAL-A) | AVERROES PHARMACEUTICALS SDN. BHD. | Compare → |
| MAL15125040AZ | KYTRON SOLUTION FOR INJECTION/INFUSION 3MG/3ML | 3.36mg 3ml | Prescription (MAL-A) | DUOPHARMA (M) SENDIRIAN BERHAD | Compare → |
| MAL19036006AZ | KYTRON TABLET 1 MG | 1.12 mg | Prescription (MAL-A) | DUOPHARMA (M) SENDIRIAN BERHAD | Compare → |
| MAL17065024AZ | Vaxcel Granisetron 1mg/ml Injection | 1.12mg 1ml | Prescription (MAL-A) | KOTRA PHARMA (M) SDN. BHD. | Compare → |
| MAL17065023AZ | Vaxcel Granisetron 1mg/ml Injection Prefilled Syringe | 1.12mg 1ml | Prescription (MAL-A) | KOTRA PHARMA (M) SDN. BHD. | Compare → |
| MAL12020019AZ | VIATRINIL 3mg/3mL Solution for Injection/ Infusion | 1.12 mg 1.00 ml | Prescription (MAL-A) | MMS PHARMA (MALAYSIA) SDN. BHD. | Compare → |
Generic Bioequivalence & Drug Substitution in Malaysia
Generic medications registered under NPRA contain the identical active pharmaceutical ingredient (API) in identical dosage strength and route of administration as the originator brand. NPRA requires rigorous bioequivalence (BE) studies demonstrating that generic drugs deliver the exact therapeutic effect. Always confirm with your doctor or community pharmacist before switching between prescription brands.